Mazumdar M - Search Results

1

Variability in response assessment in solid tumors: effect of number of lesions chosen for measurement.

Schwartz LH, Mazumdar M, Brown W, Smith A, Panicek DM. Schwartz LH, et al. Among authors: mazumdar m. Clin Cancer Res. 2003 Oct 1;9(12):4318-23. Clin Cancer Res. 2003. PMID: 14555501 Clinical Trial.

2

Response assessment classification in patients with advanced renal cell carcinoma treated on clinical trials.

Schwartz LH, Mazumdar M, Wang L, Smith A, Marion S, Panicek DM, Motzer RJ. Schwartz LH, et al. Among authors: mazumdar m. Cancer. 2003 Oct 15;98(8):1611-9. doi: 10.1002/cncr.11712. Cancer. 2003. PMID: 14534876 Free article.

3

A statistical simulation study finds discordance between WHO criteria and RECIST guideline.

Mazumdar M, Smith A, Schwartz LH. Mazumdar M, et al. J Clin Epidemiol. 2004 Apr;57(4):358-65. doi: 10.1016/j.jclinepi.2003.07.015. J Clin Epidemiol. 2004. PMID: 15135836

4

Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma.

Motzer RJ, Bacik J, Schwartz LH, Reuter V, Russo P, Marion S, Mazumdar M. Motzer RJ, et al. Among authors: mazumdar m. J Clin Oncol. 2004 Feb 1;22(3):454-63. doi: 10.1200/JCO.2004.06.132. J Clin Oncol. 2004. PMID: 14752067

5

Phase II trial of bortezomib for patients with advanced renal cell carcinoma.

Kondagunta GV, Drucker B, Schwartz L, Bacik J, Marion S, Russo P, Mazumdar M, Motzer RJ. Kondagunta GV, et al. Among authors: mazumdar m. J Clin Oncol. 2004 Sep 15;22(18):3720-5. doi: 10.1200/JCO.2004.10.155. J Clin Oncol. 2004. PMID: 15365068 Clinical Trial.

6

A theoretical approach to choosing the minimum number of multiple tumors required for assessing treatment response.

Mazumdar M, Smith A, Debroy PP, Schwartz LH. Mazumdar M, et al. J Clin Epidemiol. 2005 Feb;58(2):150-3. doi: 10.1016/j.jclinepi.2004.08.007. J Clin Epidemiol. 2005. PMID: 15680748

7

Bicalutamide for advanced prostate cancer: the natural versus treated history of disease.

Scher HI, Liebertz C, Kelly WK, Mazumdar M, Brett C, Schwartz L, Kolvenbag G, Shapiro L, Schwartz M. Scher HI, et al. Among authors: mazumdar m. J Clin Oncol. 1997 Aug;15(8):2928-38. doi: 10.1200/JCO.1997.15.8.2928. J Clin Oncol. 1997. PMID: 9256137

8

Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma.

Motzer RJ, Murphy BA, Bacik J, Schwartz LH, Nanus DM, Mariani T, Loehrer P, Wilding G, Fairclough DL, Cella D, Mazumdar M. Motzer RJ, et al. Among authors: mazumdar m. J Clin Oncol. 2000 Aug;18(16):2972-80. doi: 10.1200/JCO.2000.18.16.2972. J Clin Oncol. 2000. PMID: 10944130 Clinical Trial.

9

Measuring tumor response and shape change on CT: esophageal cancer as a paradigm.

Schwartz LH, Colville JA, Ginsberg MS, Wang L, Mazumdar M, Kalaigian J, Hricak H, Ilson D, Schwartz GK. Schwartz LH, et al. Among authors: mazumdar m. Ann Oncol. 2006 Jun;17(6):1018-23. doi: 10.1093/annonc/mdl058. Epub 2006 Apr 26. Ann Oncol. 2006. PMID: 16641170 Free article. Clinical Trial.

10

Phase II trial of irofulven (6-hydroxymethylacylfulvene) for patients with advanced renal cell carcinoma.

Berg WJ, Schwartz L, Yu R, Mazumdar M, Motzer RJ. Berg WJ, et al. Among authors: mazumdar m. Invest New Drugs. 2001;19(4):317-20. doi: 10.1023/a:1010609810517. Invest New Drugs. 2001. PMID: 11561691 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

509 results

Search Page

Filters